Shaanxi Micot Pharmaceutical Technology (02335.HK): Phase II Trial of MT200605 for Acute Ischemic Stroke Meets Primary Endpoint
NewTimeSpace News: On August 3, 2026,Shaanxi Micot Pharmaceutical Technology(02335.HK) announced that top-line data from the Phase II clinical trial of self-developed MT200605 in treating acute ischemic stroke showed the trial met the primary study endpoint.
According to the announcement, in terms of efficacy, patients in the high-dose group recorded an over 100% improvement in the likelihood of achieving favourable functional outcomes. From a safety perspective, no severe adverse events related to the investigational drug were observed, and no new significant safety risks were identified.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- MICOT PHARMA-B (02335.HK): H shares included in eligible list under Stock Connect
- Micot (02335.HK): Phase‑II Clinical Trial of MT200605 for Acute Ischemic Stroke Completed, AKI Incidence Reduced by Over 80% in High‑dose Cohort
- MICOT PHARMA-B (02335.HK): To Be Included as Hang Seng Composite Index Constituent with Effect from 7 September
- MICOT PHARMA-B (02335.HK): Three XTL6001 Studies Accepted for Presentation at EASD 2026 and ASN Kidney Week 2026, Triple-Agonist Mechanism Gains International Recognition
- MICOT PHARMA-B (02335.HK): Preclinical and Phase I data of neuroprotective candidate MT200605 accepted for oral presentation at 2026 World Stroke Congress; Phase II meets primary endpoint
